Compounding Pharmacy
503A and 503B compounding pharmacy defense, FDA warning letters, GLP-1 compounding, and USP 797/800.
Insurance Billing for Compounded GLP-1 Drugs and the Fraud Risk
Billing insurance for compounded GLP-1 preparations without matching the claim to what was actually dispensed opens False Claims A…
Med Spa GLP-1 Programs and the Supervision and Prescribing Rules
Med spas running GLP-1 programs face overlapping supervision, good faith exam, delegation and sourcing rules that vary sharply by…
Grand Jury Subpoenas to Compounding Pharmacies and the First Steps
A grand jury subpoena to a compounding pharmacy creates an immediate preservation duty and real obstruction risk, distinct from a…
Compounded GLP-1 Telehealth Prescriptions and Federal Fraud Exposure
DOJ's sham-consult, volume-prescribing fraud theory, already proven against telehealth stimulant prescribing, is the template for…
Personalized Dosing Claims for Compounded GLP-1 Drugs
FDA restricts compounded GLP-1 products that mirror a commercial drug, unless a prescriber documents a significant difference for…
Peptide Clinics and Med Spas Under FDA and State Scrutiny
Medical spa peptide programs carry FDA unapproved-drug exposure and state board scrutiny over sourcing, bulk-substance status, and…
Hormone Replacement Compounding in Men's Health Clinics
Testosterone's Schedule III status creates DEA registration, refill, and pharmacist corresponding-responsibility exposure for clin…
Compounding Pharmacy Telehealth Marketing and Kickback Risk
Per-prescription and percentage-based fees to telehealth marketers can trigger Anti-Kickback Statute and False Claims Act exposure…
Compounding for Physician Office Use Under 503B
How 503B outsourcing facilities supply physician office stock without patient-specific prescriptions, and the labeling and FDA rep…